Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2013 December;55(4) > Panminerva Medica 2013 December;55(4):391-5





A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 2013 December;55(4):391-5

language: English

Aortic valve stenosis and lipid-lowering therapy: the state of the art

Bonadei I. 1, Vizzardi E. 1, D’aloia A. 1, Gelsomino S. 2, De Cicco G. 3, Lorusso R. 3, Dei Cas L. 1

1 Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine,, University of Study of Brescia, Brescia, Italy;
2 Department of Heart and Vessels, Careggi Hospital, Florence, Italy;
3 Cardiac Surgery, Spedali Civili of Brescia, Brescia, Italy


Aortic valve stenosis is the most common native valve disease and its most common cause in the United States and Europe is the calcification of a normal trileaflet. Recently, there is increasing evidence indicating that valve calcification has common underlying mechanisms with atherosclerosis. This connection raises interest in the potential efficacy of antiatherosclerosis medications in calcific valve stenosis (AS) therapy. Among them statins, are one of the most promising candidates, because of their pleiotropic effects. The aim of this review is to summarize and analyze the findings of contemporary studies and to discuss the rationale for statin usage in AS populations.

top of page

Publication History

Cite this article as

Corresponding author e-mail